Montgomery laboratory: Metabolic Tissue Cross-Talk

Research Overview

View Dr Montgomery's latest PubMed publications listing here

Type 2 diabetes (T2D) is a major global health challenge and a major cause of heart attacks, stroke, blindness, and kidney failure. The number of individuals with diabetes has risen from 108 million in 1980 to 422 million in 2014. In addition, T2D is closely linked with liver steatosis and fibrosis. The research focus of our group is to understand the mechanisms underlying the development of hepatic steatosis and insulin resistance, with a specific interest in inter-tissue communications.

Our research focuses on understanding how the protein secretome in metabolic tissues changes in states of energy excess and/or disturbed metabolism, with the purpose of exploiting this natural biology for therapeutic gain.

Specific research projects are:

1. Assessment of liver-secreted factors in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their effects on glycaemic control.

2.The heart as a central player in tissue cross-talk - Assessment of heart-secreted factors and their effects on heart function and systemic metabolism.

3. Regulation of lipid metabolism, with a focus on beta-adrenergic signalling in adipose tissue.

4. Assessment of the therapeutic utility of NAFLD-regulated hepatokines using protein and gene therapy approaches in mouse models of obesity and type 2 diabetes.



Hamzeh Karimkhanloo, PhD

Will De Nardo, PhD

Camille Devereux, Honours

Amanuiel Taddese, Honours


Dr James Bell, University of Melbourne

Dr Kevin Watt, University of Melbourne

Prof Paul Gleeson, University of Melbourne

Prof Nigel Turner, UNSW

Prof Trevor Biden, Garvan Institute, Sydney

Prof Stephen Ting, Monash University

Prof Anthony Don, University of Sydney

Prof Todd Mitchell, University of Wollongong


2019-2022 NHMRC Project Grant. Discovery and validation of biomarkers for nonalcoholic steatohepatitis and liver fibrosis. Awarded $772,521.

2018-2022 NHMRC Career Development Fellowship. Understanding mediators of metabolic disease. Awarded $431,000.